OCS-01
AssetSmall moleculeAlso Dexamethasone ophthalmic suspension (OCS-01)
Ophthalmic formulation of dexamethasone acting as a glucocorticoid receptor agonist to reduce inflammation.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- NR3C1
- Indications
- 1
- Trials
- 2,108
- Developers
- 1
Indications
1Diabetic macular edema
Phase 3COMPLETEDNCT06172257clinicaltrials.gov7 Oct 2026
- Targets and what it contains3
- Owner and partners1
- Trials2,108
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 2 sources